Treatment as prevention

Global Antiretroviral Therapy Market (NRTI, NNRTI, Protease Inhibitors & Integrase Inhibitors): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Saturday, May 23, 2020 - 12:20am

The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.

Key Points: 
  • The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.
  • The global antiretroviral therapy market by drug type can be segmented into the following: NRTI, NNRTI, protease inhibitors and integrase inhibitors.
  • The global antiretroviral therapy market by region can be segmented into the following regions: North America, Europe and Asia Pacific.
  • The report provides a comprehensive analysis of the global antiretroviral therapy market with potential impact of COVID-19.

ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic

Monday, April 27, 2020 - 2:54pm

To contribute to finding solutions, ViiV Healthcare is proud to announce the Global HIV and COVID-19 Emergency Fund.

Key Points: 
  • To contribute to finding solutions, ViiV Healthcare is proud to announce the Global HIV and COVID-19 Emergency Fund.
  • Through this fund, we can support research about the impact of COVID-19 on people living with HIV that is urgently needed.
  • The Research Emergency Response Fund will make available up to 1.5 million to support scientific research about the impact of COVID-19 on people living with HIV.
  • The Community Emergency Response Fund will support existing grantees of ViiV Healthcares Positive Action or Government Affairs (GA) or Global Public Health (GPH).

ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

Monday, March 9, 2020 - 2:15pm

These data were presented today at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, Massachusetts.

Key Points: 
  • These data were presented today at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, Massachusetts.
  • Kimberly Smith, M.D., Head of Research & Development at ViiV Healthcare, said: We now have positive data showing the effectiveness and safety of a long-acting HIV treatment that is administered every two months.
  • We also have patient preference data showing that study participants overwhelmingly preferred both the monthly and every-two-month long-acting regimens, over oral treatment.
  • 1Study evaluating the efficacy, safety, and tolerability of long-acting cabotegravir plus long-acting rilpivirine administered every 8 weeks in virologically suppressed HIV-1-infected adults.

HIV Survey Finds Treatments Positively Impact Viral Suppression, Yet Stigma Impacts Quality of Life

Monday, January 27, 2020 - 7:00pm

PHILADELPHIA, Jan. 27, 2020 /PRNewswire/ -- A new survey from Health Union, HIV In America 2019, finds that despite the positive impact of treatments that lead to viral suppression, people living with HIV continue to face various stigmas and stresses that negatively impact their lives.

Key Points: 
  • PHILADELPHIA, Jan. 27, 2020 /PRNewswire/ -- A new survey from Health Union, HIV In America 2019, finds that despite the positive impact of treatments that lead to viral suppression, people living with HIV continue to face various stigmas and stresses that negatively impact their lives.
  • Continued use of antiretroviral therapy is critical to achieving viral suppression and reducing a person's viral load to an undetectable level.
  • HIV In America 2019 respondents appear to represent a greater percentage of people who are virally suppressed compared to the national HIV population.
  • However, despite the impact of treatments for survey respondents, the findings indicated that various stresses remain.

CytoDyn Announces CROI’s Acceptance of Late-Breaking Abstract by Dr. Jonah Sacha for use of Leronlimab as PrEP

Monday, January 27, 2020 - 11:00am

Therefore, the development of new, highly effective, and long-acting PrEP modalities with high patient uptake is urgently needed.

Key Points: 
  • Therefore, the development of new, highly effective, and long-acting PrEP modalities with high patient uptake is urgently needed.
  • The acceptance of Dr. Sachas late-breaking abstract describing leronlimabs utility in HIV prevention underscores the potential of leronlimab for treatments beyond suppression of established HIV infection.
  • Leronlimab could offer a much needed, simple and long-lasting preventative treatment option for people at risk of HIV infection.
  • The results from this study are extremely promising and further support our efforts to begin clinical trials for leronlimab as a PrEP treatment.

ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Thursday, December 5, 2019 - 12:05pm

Challenges with tolerability, safety, and drug-to-drug interactions may further decrease the number of acceptable antiretroviral therapies available to design effective treatment regimens.

Key Points: 
  • Challenges with tolerability, safety, and drug-to-drug interactions may further decrease the number of acceptable antiretroviral therapies available to design effective treatment regimens.
  • There remains an unmet need for these individuals who are considered heavily treatment-experienced and who are unable to successfully suppress their HIV.
  • We look forward to working with the FDA to make fostemsavir available to the people in the US who need it.
  • This submission is supported by the data from the pivotal phase III BRIGHTE study in heavily treatment-experienced people living with multidrug-resistant HIV.

New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors

Monday, November 25, 2019 - 11:45am

It's time to elevate a real conversation about HIV and sexual health among America's young people, and roll out innovative and engaging initiatives to educate and fight HIV stigma."

Key Points: 
  • It's time to elevate a real conversation about HIV and sexual health among America's young people, and roll out innovative and engaging initiatives to educate and fight HIV stigma."
  • Meanwhile, the survey demonstrated that HIV stigma persists among young adults in the U.S., which is negatively impacting how young people with HIV are being treated.
  • Importantly, the survey demonstrated that young adults are not being accurately informed about how HIV can and cannot be transmitted.
  • The survey showed that many young adults aren't being accurately informed about the meaning of an undetectable viral load.

International HIV Experts Call for Focus on Quality of Life Beyond Viral Suppression

Monday, November 18, 2019 - 10:47am

Recommendations in the white paper, which have been summarised in AIDS Reviews ,1 focus on a new HIV care framework - Health Goals for Me.

Key Points: 
  • Recommendations in the white paper, which have been summarised in AIDS Reviews ,1 focus on a new HIV care framework - Health Goals for Me.
  • The recommendations were developed to support an holistic and individualised long-term treatment approach that goes beyond viral load and CD4 count, to assess health-related quality of life.
  • However, this brings new challenges relating to long-term health; as increasing numbers of people navigate their lives beyond viral suppression and look towards improved quality of life.
  • This international consensus represents an important first step to improve care beyond viral load and ultimately improve the lives of people living with HIV.

Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis

Friday, October 4, 2019 - 12:30pm

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have been committed to the fight against HIV for more than 25 years.

Key Points: 
  • The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have been committed to the fight against HIV for more than 25 years.
  • "Although HIV is now considered a chronic and manageable condition, people living with HIV still face a lifetime of taking daily pills.
  • With 37 million people around the world living with HIV and nearly two million people newly-infected each year we cannot treat ourselves out of the HIV epidemic.
  • Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson.

Janssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two Months

Thursday, August 22, 2019 - 7:02am

CORK,Ireland, Aug. 22, 2019 /PRNewswire/ --The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have announced positive top-line results from the Phase 3 ATLAS-2M study of the investigational, long-acting two-drug injectable regimen of its rilpivirine and ViiV Healthcare's cabotegravir for the treatment of HIV.

Key Points: 
  • CORK,Ireland, Aug. 22, 2019 /PRNewswire/ --The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have announced positive top-line results from the Phase 3 ATLAS-2M study of the investigational, long-acting two-drug injectable regimen of its rilpivirine and ViiV Healthcare's cabotegravir for the treatment of HIV.
  • The study is being conducted at research centers in Australia, Argentina, Canada, France, Germany, Italy, Mexico, Russia, South Africa, South Korea, Spain, Sweden and the United States.
  • Detailed results from the ATLAS-2M study will be presented at an upcoming scientific meeting.
  • Janssen Sciences Ireland UC is a member of the Janssen Pharmaceutical Companies of Johnson & Johnson.